<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES:: We sought to predict <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-associated <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> during modified FOLFOX6 (mFOLFOX6) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS:: Equal numbers of male and female patients with previously untreated, primary or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> were followed through a first course of mFOLFOX6 with 85 mg/m <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> every 2 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Accounting for correlation among a subject's cycle, logistic regression estimated per cycle risk of <z:hpo ids='HP_0011009'>acute</z:hpo> (under 14 d) and persistent (14 d or more) <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Proportional hazards regression predicted time to persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS:: Among mFOLFOX6 recipients (n=50, age 58.9Â±10.1 y), 36% received concomitant bevacizumab </plain></SENT>
<SENT sid="5" pm="."><plain>Of the total number of cycles, 94.2% (422/448) were evaluable </plain></SENT>
<SENT sid="6" pm="."><plain>Most (84%) subjects reported <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> at least once; 74% reported <z:hpo ids='HP_0011009'>acute</z:hpo> and 48% reported persistent symptoms </plain></SENT>
<SENT sid="7" pm="."><plain>On multivariate analysis, risk factors shared by <z:hpo ids='HP_0011009'>acute</z:hpo> and persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> were body surface area &gt;2.0, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> in a past cycle, and lower body weight </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, risk of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> decreased with age (adjusted for renal function and winter season), whereas risk of persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> increased with cumulative dose of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> in a past cycle </plain></SENT>
<SENT sid="9" pm="."><plain>Concomitant bevacizumab was not a risk factor when administered in stage IV disease but was associated with persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> when administered experimentally in stage III </plain></SENT>
<SENT sid="10" pm="."><plain>Females had no increased risk of either form of <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>After 3 cycles, weight, body surface area, and prior <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> predicted time to persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS:: Routinely available clinical factors predict <z:hpo ids='HP_0011009'>acute</z:hpo> and persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> associated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>When validated, the proposed prognostic score for persistent <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> can help clinicians counsel patients about chemotherapy </plain></SENT>
</text></document>